Latest Conference Articles

Brogan discusses the various opportunities and challenges that have accompanied recent evolutions in inflammatory bowel disease management.

Stewart reviews clinical pearls for performing rectal exams and explains common mistakes and misdiagnoses as well as how to avoid them.

Moore discusses the importance of individualizing PBC treatment now that multiple second-line therapies are available.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

Gandhi describes the crucial role APPs play in GI bleeding care and the importance of collaborative management of these patients.

Ugras describes recent evolutions in EoE, including new FDA-approved therapies, updated clinical guidelines, and better understanding of its pathophysiology.

Saggese describes recent evolutions in MASH care with the FDA approval of semaglutide and the continued importance of diet, physical activity, and weight management.

Brogan explains how to navigate the complexities of the Crohn’s disease treatment landscape and why patients need to be included in the decision making process.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Skarbinski explains challenges providers face when managing refractory GERD and common misconceptions about its diagnosis and treatment.

Moore describes recent progress in PBC and PSC and how this defined the field of hepatology in 2024, with lasting effects into 2025.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Stewart explains recent advances in eosinophilic gastrointestinal diseases and breaks down new ACG EoE guidelines.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

Despite an excellent safety and tolerability profile and proven efficacy in treating atrial fibrillation, PFA failed to prove superiority to RA.

Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.

Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.

The investigative aldosterone synthase inhibitor reduced seated systolic blood pressure in patients with uncontrolled or resistant hypertension compared to placebo.

Aficamten shows significant benefits over metoprolol in treating symptomatic obstructive HCM, potentially changing first-line therapy approaches.

Aficamten displayed superior improvements in peak oxygen uptake and hemodynamics compared to the most commonly used beta-blocker for symptomatically obstructive HCM.

Take a look at 7 major clinical trials to keep an eye on for the upcoming ESC Congress from August 29-September 1, 2025.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.